stage IV childhood small noncleaved cell lymphoma
Showing 1 - 25 of >10,000
AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell
Completed
- AIDS-related Diffuse Large Cell Lymphoma
- +8 more
- cyclophosphamide
- +7 more
-
Eldoret, Kenya
- +1 more
Sep 12, 2022
Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2
Active, not recruiting
- Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma
- +22 more
- External Beam Radiation Therapy
- Orbital Radiation
-
Houston, TexasM D Anderson Cancer Center
Dec 9, 2022
Non Small Cell Lung Cancer Metastatic Trial (MRI)
Not yet recruiting
- Non Small Cell Lung Cancer Metastatic
- MRI
- (no location specified)
May 16, 2023
Double-dose Furmonertinib in Treatment of Slow
Not yet recruiting
- Non Small Cell Lung Cancer
- +3 more
- (no location specified)
Oct 31, 2023
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in
Not yet recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +2 more
- Cetuximab
- +2 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 2, 2023
Hematopoietic and Lymphoid Cell Tumor, Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma Trial in Seattle
Terminated
- Hematopoietic and Lymphoid Cell Neoplasm
- +12 more
- Laboratory Biomarker Analysis
- ROR1 CAR-specific Autologous T-Lymphocytes
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 11, 2022
Orelabrutinib in Treatment of Chronic Lymphocytic Leukemia/Small
Recruiting
- CLL/SLL
-
Jinan, Shandong, ChinaDepartment of Hematology, Shandong Provincial Hospital Affiliate
Jun 16, 2023
NSCLC Without Mutation in Epidermal Growth Factor Receptor (Disorder) Trial (tereotactic body radiotherapy)
Not yet recruiting
- Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)
- tereotactic body radiotherapy
- (no location specified)
Dec 1, 2023
China With Non-Small-Cell Lung Cancer That is Unable to be
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- (no location specified)
May 16, 2023
Non Small Cell Lung Cancer Trial in Shanghai (CS1001 mAb, CS1001 )
Active, not recruiting
- Non Small Cell Lung Cancer
- CS1001 monoclonal antibody
- CS1001 placebo
-
Shanghai, Shanghai, ChinaShanghai Pulmonary Hospital
Nov 8, 2022
Stage IV NSCLC Trial in Wuhan (SBRT+Osimertinib, Osimertinib 80 MG)
Not yet recruiting
- Stage IV Non-small Cell Lung Cancer
- SBRT+Osimertinib
- Osimertinib 80 MG
-
Wuhan, Hubei, ChinaTongji Hospital Affiliated to Tongji Medical College of Huazhong
Oct 13, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (Chemotherapy, Pembrolizumab, Ramucirumab)
Not yet recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Chemotherapy
- +2 more
- (no location specified)
Jan 9, 2023
Recurrent NSCLC, Stage IIIA NSCLC, Stage IIIB NSCLC Trial in Buffalo (therapeutic lymphadenectomy (TEMLA) and Stereotactic Body
Completed
- Recurrent Non-small Cell Lung Cancer
- +3 more
- therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)
- quality-of-life assessment
-
Buffalo, New YorkRoswell Park Cancer Institute
Jul 20, 2022
NSCLC Metastatic Trial in Chengdu (Camrelizumab, stereotactic body radiation therapy, Chemotherapy)
Recruiting
- Non-small Cell Lung Cancer Metastatic
- Camrelizumab
- +2 more
-
Chengdu, Sichuan, ChinaSichuan Cancer Hospital & Institute
Jul 21, 2022
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma Trial
Completed
- Anaplastic Large Cell Lymphoma, ALK-Negative
- +9 more
- Autologous Hematopoietic Stem Cell Transplantation
- +8 more
-
Duarte, California
- +7 more
Nov 4, 2022
NSCLC (NSCLC) Trial (Sotorasib, Pembrolizumab)
Not yet recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- (no location specified)
Jun 26, 2023
Unresectable Melanoma, Metastatic Melanoma, Stage III NSCLC Trial in Louisville, New York (IOV-4001)
Recruiting
- Unresectable Melanoma
- +3 more
- IOV-4001
-
Louisville, Kentucky
- +2 more
Nov 21, 2022
Stage IIIB(N2) NSCLC, Stage IIA NSCLC, Stage IIB NSCLC Trial in Beijing (Pembrolizumab 200 mg IV infusion)
Not yet recruiting
- Stage IIIB(N2) Non-small Cell Lung Cancer
- +3 more
- Pembrolizumab 200 mg IV infusion
-
Beijing, Beijing, ChinaPeking University
May 30, 2023
Stage IIIB NSCLC AJCC v7, Stage IV NSCLC AJCC v7 Trial in Portland (Laboratory Biomarker Analysis, Paclitaxel, Pharmacological
Completed
- Stage IIIB Non-Small Cell Lung Cancer AJCC v7
- Stage IV Non-Small Cell Lung Cancer AJCC v7
- Laboratory Biomarker Analysis
- +3 more
-
Portland, OregonOHSU Knight Cancer Institute
Sep 14, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, biological, drug)
Not yet recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Biospecimen Collection
- +5 more
- (no location specified)
Sep 7, 2023
Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Atlanta (Aldesleukin,
Not yet recruiting
- Lung Non-Small Cell Carcinoma
- +3 more
- Aldesleukin
- Pembrolizumab
-
Atlanta, GeorgiaEmory University/Winship Cancer Institute
Aug 8, 2022
NSCLC (NSCLC), Stage IV Trial in Switzerland (Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy),
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Stage IV
- Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)
- +2 more
-
Aarau, Switzerland
- +7 more
Oct 27, 2023
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in
Recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +3 more
- Biopsy
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 9, 2023
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Non-Small Cell Cancer AJCC v7
Active, not recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +5 more
- Laboratory Biomarker Analysis
- +3 more
-
New Haven, Connecticut
- +4 more
Jan 27, 2023
NSCLC (NSCLC) Trial in Shanghai (Tumor treating fields(EFE-P100), Docetaxel injection)
Not yet recruiting
- Non-small Cell Lung Cancer (NSCLC)
- Tumor treating fields(EFE-P100)
- Docetaxel injection
-
Shanghai, ChinaShanghai Pulmonary Hospital
Dec 21, 2022